1-2 of 2
Aileen Cleary Cohen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Zanubrutinib is well tolerated and effective in CLL/SLL patients intolerant of ibrutinib/acalabrutinib: Updated results

Open Access
Clinical Trials & Observations
Mazyar Shadman, John M. Burke, Jennifer Cultrera, Habte A. Yimer, Syed F. Zafar, Jamal Misleh, Subramanya S. Rao, Charles M. Farber, Aileen Cleary Cohen, Hui Yao, Adam Idoine, Qi An, Ian W. Flinn, Jeff P. Sharman
Journal: Blood Advances
Blood Adv bloodadvances.2024015493.
https://doi.org/10.1182/bloodadvances.2024015493
Published: 2025
Includes: Supplemental data
Journal Articles

Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study

Open Access
Clinical Trials & Observations
Jennifer R. Brown, Jessica Li, Barbara F. Eichhorst, Nicole Lamanna, Susan M. O’Brien, Constantine S. Tam, Lugui Qiu, Ruiqi Huang, Yang Shi, Adam Idoine, Tommi Salmi, Aileen Cleary Cohen, Mazyar Shadman
Journal: Blood Advances
Blood Adv (2025) 9 (8): 1918–1926.
https://doi.org/10.1182/bloodadvances.2024014206
Published: 2025
Includes: Supplemental data